Biopolym. Cell. 2013; 29(4):277-282.
http://dx.doi.org/10.7124/bc.000822
Reviews
Development of molecular oncohematology in Ukraine
1Telegeev G. D., 1Dybkov M. V., 1Dubrovska A. N., 1Miroshnichenko D. A., 1Tyutyunnykova A. P., 1Maliuta S. S.
  1. Institute of Molecular Biology and Genetics, NAS of Ukraine
    150, Akademika Zabolotnoho Str., Kyiv, Ukraine, 03680

Abstract

Disruption of the genetic component of cells are mandatory element of malignant transformation. For the majority of blood neoplasias genetic disorders have been discovered, and they can be used for diagnosis and appropriate therapy. The data obtained by authors about the role of domains of Bcr-Abl protein (the main etiological factor in the pathogenesis of leukemia with Ph-chromosome) are presented in this review as well as approved diagnostic methods for myeloproliferative disorders and acute leukemias.
Keywords: myeloproliferative neoplasms, Bcr-Abl, Jak2, molecular pathogenesis, diagnostics
Full text: (PDF, in English)

References

[1] Fedorenko Z. P., Goulak L. O., Gorokh Y. L., Ryzhov A.Yu., Soumkina O. V., Koutsenko L. B. Cancer in Ukraine, 2011–2012. Incidence, mortality, activities of oncological service Bull. Nat. Cancer Registry of Ukraine. Ed. I. B. Shchepotin Kyiv, 2013 73 p.
[2] Tefferi A., Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding and treatment strategies J. Clin. Oncol 2011 29, N 5:573–582.
[3] Glusman D. F., Sklyarenko L. M., Nadgornaya V. A. Diagnostic oncohematology Kyiv: DIA, 2011 254 p.
[4] Tefferi A., Vardiman J. W. Classification and diagnosis of myeloproliferative neoplasms. The 2008 World Health Organization criteria and point-of-care diagnostic algorithms Leukemia 2008 22, N 1:14–22.
[5] Swerdlow S. H., Campo E., Harris et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues / Fourth Edition Lyon: IARC Press, 2008 439 p.
[6] Telegeev G. D., Dybkov M. V., Karpenko O. I., Cherepenko H. I. Molecular basis of Ph'leukemia and finding the way to treat them Biopolym. Cell 1994 10, N 5:78–92.
[7] Telegeev G. D., Dybkov M. V., Bozhko M. V., Tretiak N. M., Maliuta S. S. Molecular-biology approaches to detection of Philadelphia chromosome in patients with leukemia Biopolym. Cell 1996 12, N. 6:63–68.
[8] Teleheiev HD, Dybkov MV, Bozhko MV, Tretiak NM, Maliuta SS. [The molecular biology diagnosis of neoplastic blood diseases]. Tsitol Genet. 1998;32(1):71-8. Ukrainian.
[9] Telegeev G. D., Dybkov M. V., Bojko M. V., Demidenko D. V., Maliuta S. S., Tretyak N. M., Bondar M. V. Monitoring of chronic myeloid leukemia by molecular-biological methods [guidelines] Kyiv: The National Centre for Scientific Health Information Health of Ukraine publ., 1997 16 p.
[10] Sawyers C. L., McLaughlin J., Goga A., Havlik M., Witte O. The nuclear tyrosine kinase c-Abl negatively regulates cell growth Cell 1994 77, N 1:121–131.
[11] Telegeev G. D., Dybkov M. V., Dubrovska A. N., Maliuta S. S. Deletion of the fifth exon of bcr/abl gene by acute lymphoblastic leukosis with Ph' chromosome Biopolym. Cell 2001 17, N 4:298–301.
[12] Dybkov M. V., Telegeev G. D., Dubrovskaya A. N., Maliuta S. S. Deletion in dbl domain of bcr/abl gene in leukemia patients with Ph' chromosome Exp. Oncol 2002 24, N 2:153–154.
[13] Popovici C., Cailleres S., David M., Lafage-Pochitaloff M., Sainty D., Mozziconacci M. J. E6a2 BCR-ABL fusion with BCR exon 5-deleted transcript in a Philadelphia positive CML responsive to Imatinib Leuk. Lymphoma 2005 46, N 9:1375–1377.
[14] Colla S., Sammarelli G., Voltolini S., Crugnola M., Sebastio P., Giuliani N. E6a2 BCR-ABL transcript in chronic myeloid leukemia: is it associated with aggressive disease? Haematologica 2004 89, N 5:611–613.
[15] How G. F., Lim L. C., Kulkarni S., Tan L. T., Tan P., Cross N. C. Two patients with novel BCR/ABL fusion transcripts (e8/a2 and e13/a2) resulting from translocation breakpoints within BCR exons Br. J. Haematol 1999 105, N 2:434–436.
[16] Moreno Mdel P., Cortinas M. N., Bonomi R., Cardeza A., Uriarte Mdel R. A novel BCR-ABL fusion transcript (e15a2) in 2 patients with atypical chronic myeloproliferative syndrome Blood 2001 97, N 11:3668–3669.
[17] Harnois T., Constantin B., Rioux A., Grenioux E., Kitzis A., Bourmeyster N. Differential interaction and activation of Rho family GTPases by p210 bcr-abl and p190 bcr-abl Oncogene 2003 22, N 41:6445–6454.
[18] McWhirter J. R., Wang J. Y. Effect of Bcr sequences on the cellular function of the Bcr-Abl oncoprotein Oncogene 1997 15, N 14:1625–1634.
[19] Dubrovskaya A. N., Telegeev G. D., Dybkov M. V., Voloshanenko O. S., Shved V. V., Maliuta S. S. Mutation analysis and bacterial expression of the chimerical oncoprotein Bcr/Abl Dbl-homology domain Biopolym. Cell 2002 18, N 2:96–101.
[20] Telegeev G. D., Dubrovska A. N., Dybkov M. V., Maliuta S. S. Influence of Bcr/Abl fusion proteins on the course of Ph leukemias Acta Biochim. Polon 2004 51, N 3:845–849.
[21] Oleksy A., Opalinski L., Derewenda U., Derewenda Z. S., Otlewski J. The molecular basis of RhoA specificity in the guanine nucleotide exchange factor PDZ-RhoGEF J. Biol. Chem 2006 281, N 43:32891–32897.
[22] Miroshnychenko D. O, Teleheiev H. D., Maliuta S. S. Analysis of GEF activity of Bcr protein DH domain Ukr. Biokhim. Zh 2007 79, N 5:116–121.
[23] Miroshnychenko D., Dubrovska A, Maliuta S., Telegeev G., Aspenstrom P. Novel role of pleckstrin homology domain of the Bcr-Abl protein: analysis of protein-protein and protein-lipid interactions Exp. Cell Res 2010 316, N 4 P. 530–542.
[24] Miroshnychenko D. O., Dubrovska A. M., Telegeev G. D., Maliuta S. S. Protein-lipid and protein-protein interactions of Bcr PH domain Biopolym. Cell 2007 23, N 5:405–409.
[25] Czech M. P. Dynamics of phosphoinositides in membrane retrieval and insertion Annu. Rev. Physiol 2003 65:791–815.
[26] Lemmon M. A., Ferguson K. M. Molecular determinants in pleckstrin homology domains that allow specific recognition of phosphoinositides Biochem. Soc. Trans 2001 29, Pt 4 P. 377– 384.
[27] Olabisi O. O., Mahon G. M., Kostenko E. V., Liu Z., Ozer H. L., Whitehead I. P. Bcr interacts with components of the endosomal sorting complex required for transport-I and is required for epidermal growth factor receptor turnover Cancer Res 2006 66, N 12:6250–6257.
[28] Reddy M. M., Fernandes M. S., Salgia R., Levine R. L., Griffin J. D., Sattler M. NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases Leukemia 2011 25, N 2:281–289.
[29] Cortes J., Jabbour E., Kantarjian H. et al. Dynamics of BCRABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors Blood 2007 110, N 12:4005–4011.
[30] Dybkov M. V., Gartovska I. R., Telegeev G. D., Maliuta S. S. Development of test system for detection of V617F mutation of Jak2 gene in patients with chronic myeloproliferative disorders Science and Innovation 2009 5, N 6:59–63.
[31] Glusman D. F., Sklyarenko L. M., Nadgornaya V. A., Zavelevich M. P., Poludnenko L. Yu., Ivanovskaya T. S., Ukrainskaya N. I., Telegeev G. D., Dybkov M. V., Polischuk L. A. Development of complex of immunocytochemical and molecular genetic technologies of acute leukemias diagnostics and their implementation into clinical practice Science and Innovation 2013 9, N 1:44–54.